Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lucentis Brings New Label Format Into Focus; Highlights List Most Warnings

Executive Summary

Genentech's macular degeneration therapy Lucentis (ranibizumab) is the first product to carry FDA's new physician labeling format

You may also be interested in...



Lucentis Approval For Wet AMD Includes Less Frequent Dosing Option

FDA's June 30 approval of Genentech's Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration includes the possibility for less frequent, quarterly dosing

Lucentis Approval For Wet AMD Includes Less Frequent Dosing Option

FDA's June 30 approval of Genentech's Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration includes the possibility for less frequent, quarterly dosing

Labeling Format Differentiation Minimized By Rule Implementation Timeline

FDA's implementation timeline for the physician labeling rule may mean that advent of the new labeling format will have limited impact on currently available competing products

UsernamePublicRestriction

Register

PS047363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel